Maravai Lifesciences Holdings, Inc. · NASDAQ:MRVI

Maravai Lifesciences — Q2 2025 Earnings Presentation

21 slides from Maravai Lifesciences's earnings presentation, Aug 11, 2025

  1. Slide 1: Q2 2025 Financial Results

    NASDAQ: MRVI Q2 2025 Financial Results August 11, 2025

  2. Slide 2: Agenda

    Agenda 01 Welcome Deb Hart, Head of Investor Relations 02 Business Updates Bernd Brust, Chief Executive Officer 03 Financial Results Raj Asarpota, Chief Financial Officer 04 Q&A Session Bernd Brust, Chief Executive Officer Raj Asarpota, Chief Financial Officer 2 © 2025 Maravai LifeSciences

  3. Slide 3: Forward Looking Statements and Use of Non-GAAP Financial Measures

    Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains, and our officers and representatives may, from time to time make, “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.

  4. Slide 4: Business Updates

    Q2 2025 Business Updates Bernd Brust Chief Executive Officer 4 © 2025 Maravai LifeSciences

  5. Slide 5: Bernd Brust, Maravai's Chief Executive Officer & Member of the Board of Directors

    Bernd Brust, Maravai’s Chief Executive Officer & Member of the Board of Directors • Appointed CEO and Member of the Board on June 9, 2025 • Corporate builder, operator and driver of transformation for over 30 years • Deep experience at technology-based life science companies, including multiple CEO

  6. Slide 6: Shifting our Strategy to Position Maravai for Sustainable, Profitable Growth

    Shifting our Strategy to Position Maravai for Sustainable, Profitable Growth 1 Commitment to • Restructuring plan targeting more than $50 million in annual cost savings improve • Strategic realignment of organization to functional operating model operational execution • Driving efficiency and execut

  7. Slide 7: Raj Asarpota, Maravai's Chief Financial Officer

    Raj Asarpota, Maravai’s Chief Financial Officer • Appointed CFO on June 30, 2025 • Strategic finance leader with deep experience guiding companies through periods of transformation and growth • CFO roles at both private and public life sciences and medical device companies • In his role, will lead g

  8. Slide 8: Financial Results

    Q2 2025 Financial Results Raj Asarpota Chief Financial Officer 8 © 2025 Maravai LifeSciences

  9. Slide 9: Q2 2025 Results

    Q2 2025 Results Business Segment Customer Mix Geographical Mix REVENUE $47.4 M • NAP revenue of $31.1 M • BioPharma: 28% • NA: 65% • BST revenue of $16.3 M • Life Sciences & Diagnostics: 30% • EMEA: 18% • Academia: 8% • Asia Pacific: 12% • CRO/CMO/CDO: 7% • China: 5% • Distributor: 27% 9 © 2025 Mara

  10. Slide 10: Financial Overview

    Financial Overview Adjusted GAAP Net Loss of Adjusted EBITDA of EBITDA Margin of $69.8 M1, 2 ($10.4 M)3 (22%) 1. GAAP net loss prior to amounts attributable to non-controlling interests 2. Includes a non-cash goodwill impairment charge of $30.4 M 3. Adjusted EBITDA reconciliation provided on pages 1

  11. Slide 11: Basic, Diluted and Adjusted EPS

    Basic, Diluted and Adjusted EPS Loss Per Share ($)1,2,3 $0.00 -$0.05 -$0.10 ($0.08) -$0.15 -$0.20 -$0.25 ($0.27) ($0.27) -$0.30 Basic EPS Diluted EPS Adjusted EPS 1. Basic EPS (GAAP) equals Net Income (loss) attributable to our Class A shares divided by the weighted average Class A shares 2. In peri

  12. Slide 12: Q2 2025 Balance Sheet, Cash Flow and Financial Highlights

    Q2 2025 Balance Sheet, Cash Flow and Financial Highlights Long-Term Cash Net Cash1 Gross Debt $270 M $297 M ($27 M) Cash Used in Operations Fully Diluted $10.3 M in Q2 2025 Net Interest Stock-based Shares Expense Compensation Outstanding2 $3.8 M $6.8 M 255 M 1. Based on Cash less long-term debt 2. T

  13. Slide 13: Q2 2025 Business Segment Financials

    Q2 2025 Business Segment Financials Nucleic Acid Production ($M) Biologics Safety Testing ($M) REVENUE REVENUE $31.1 M $16.3 M • 66% of total Maravai revenue • 34% of total Maravai revenue • ($7.3 M) Adjusted EBITDA1,2 • $10.9 M Adjusted EBITDA1,2 1. Reconciliation provided on pages 19-21 2. Refers

  14. Slide 14: Cost Reduction initiatives across the organization

    Cost Reduction initiatives across the organization >$50 M Labor Facilities CAPEX Controllables Total 14 © 2025 Maravai LifeSciences

  15. Slide 15: Q&A

    Q&A 15 © 2025 Maravai LifeSciences

  16. Slide 16: Closing Commentary

    Q2 2025 Closing Commentary Bernd Brust Chief Executive Officer 16 © 2025 Maravai LifeSciences

  17. Slide 17: Closing Remarks

    Closing Remarks Return to positive Committing to Operational Focus on Revenue Growth Adjusted EBITDA and Free Excellence and Diversification Cash Flow in 2026 17 © 2025 Maravai LifeSciences

  18. Slide 18: Thank you

    Thank you maravdali LifeSciences

  19. Slide 19: Non-GAAP reconciliations

    Non-GAAP reconciliations Net Loss to Adjusted EBITDA (non-GAAP) This presentation contains financial measures that have not Three Months Ended Six Months Ended been calculated in accordance with accounting principles In thousands generally accepted in the U.S. (GAAP). These non-GAAP June 30, June 30

  20. Slide 20: Non-GAAP reconciliations

    Non-GAAP reconciliations Net Loss attributable to Maravai Life Sciences Holdings, Inc. to Adjusted Net Loss (non-GAAP) and Adjusted Fully Diluted Loss Per Share (non-GAAP) These non-GAAP measures are supplemental measures of operating performance that are not prepared in accordance Three Months Ende

  21. Slide 21: Explanatory Notes to Reconciliations

    Explanatory Notes to Reconciliations (1) Refers to the change in the estimated fair value of contingent consideration related to completed acquisitions. (2) Refers to incremental costs incurred to execute and integrate completed acquisitions, including retention payments related to integration that

Maravai LifeSciences Holdings — Q2 2025 Earnings Presentation on 6ix